Latest total current liabilities for EMMAW: $73M.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
Emmaus Life Sciences (EMMAW) currently reports a total current liabilities of $73M as of September 2026. That compares with $64M in the prior-year period — up 13.6% year over year. Use the charts on this page to explore Emmaus Life Sciences's total current liabilities history and peer comparisons.
Emmaus Life Sciences's total current liabilities increased from $64M to $73M — a 13.6% year-over-year increase (period ending September 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
Emmaus Life Sciences reported $73M in total current liabilities as of September 2026. That compares with $64M in the prior-year period — up 13.6% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.
Start with the current total current liabilities of $73M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Emmaus Life Sciences, and consider following EMMAW for alerts when major investors trade the stock.
Emmaus Life Sciences is classified in the Healthcare sector. On total current liabilities, it currently shows $73M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing EMMAW with unrelated industries.